PATENT CLAIM ANALYSIS

Application Number: 16112453
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Claim (Index 2):
The method of  claim 2 , wherein the antisense oligonucleotide is administered intravenously.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 96.0
- Lexical Diversity: 1.10345
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14740097', '13826880', '14857555', '12837356', '14852149']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7986779567441143
- 35 USC 102 Novelty (BERT): 0.6736345385551681
- Combined Prediction Score: 0.7861736149252198
- Mean Citation Score: 784.452464
- Max Citation Score: 785.00397
- Similarity Product: 623.7883995071161

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test